Alzheimer's Disease Neuroimaging Initiative 2

Summary

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Conditions

• Mild Cognitive Impairment (MCI)
• Alzheimer's Disease (AD)
• Significant Memory Concern (SMC)
• Early Mild Cognitive Impairment (EMCI)
• Late Mild Cognitive Impairment (LMCI)

Interventions

DRUG

Florbetapir

Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

DRUG

Flortaucipir

Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Sponsors & Collaborators

• Northern California Institute of Research and Education

  collaborator OTHER

• National Institute on Aging (NIA)

  collaborator NIH

• Alzheimer's Therapeutic Research Institute

  collaborator OTHER

• University of Southern California

  lead OTHER

Principal Investigators

• Ronald Petersen, MD, PhD · Mayo Clinic

• Michael W. Weiner, MD · University of California, San Francisco

• Paul S. Aisen, MD · University of Southern California

Eligibility

Min Age

55 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2011-02-14

Primary Completion

2017-11-29

Completion

2017-11-29

FDA Drug

Yes

Countries

• United States
• Canada

Study Locations